Identification of four serum microRNAs from a genome-wide serum microRNA expression profile as potential non-invasive biomarkers for endometrioid endometrial cancer

Oncology Letters

Volumn 6, Issue 1, 2013, Pages 261-267

  Jia, Wenhui ^a   Wu, Yuanzhe ^b   Zhang, Qin ^b   Gao, Ge ^a   Zhang, Chenyu ^a   Xiang, Yang ^a  

^a NANJING UNIVERSITY   (China)

^b JINLING HOSPITAL   (China)

Author keywords

Biomarker; Diagnosis; Endometrioid endometrial cancer; Serum microRNAs

Indexed keywords

CA 125 ANTIGEN; MICRORNA; MICRORNA 126; MICRORNA 155; MICRORNA 16; MICRORNA 186; MICRORNA 204; MICRORNA 222; MICRORNA 223; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER RISK; CHEMILUMINESCENCE IMMUNOASSAY; CLINICAL ARTICLE; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIOID CARCINOMA; ENDOMETRIUM CANCER; FEMALE; HUMAN; PROTEIN EXPRESSION; PROTEIN MICROARRAY; REAL TIME POLYMERASE CHAIN REACTION; RECEIVER OPERATING CHARACTERISTIC; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SCORING SYSTEM; UPREGULATION;

EID: 84878318949     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2013.1338     Document Type: Article

References (49)

1. Zhang Y and Wang J: Controversies in the management of endometrial carcinoma. Obstet Gynecol Int 2010: 862908, 2010
2. Ries LAG, Melbert D, Krapcho M, Mariotto A, Miller BA, Feuer EJ, et al (eds): SEER Cancer Statistics Review, 1975-2004. National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/csr/1975_2004/.
3. Di Saia PJ and Creasman WT: Clinical Gynecologic Oncology. 6th edition. St. Louis, Mosby, 2002.
4. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E and Vergote I:Endometrial cancer. Lancet 366: 491-505, 2005.
5. Bokhman JV: Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15: 10-17, 1983.
6. Mutter GL, Lin MC, Fitzgerald JT, Kum JB, Baak JP, et al: Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92: 924-930, 2000.
7. Shang Y: Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat Rev Cancer 6: 360-368, 2006.
8. Sebastianelli A, Renaud MC, Grégoire J, Roy M and Plante M: Preoperative CA 125 tumour marker in endometrial cancer: correlation with advanced stage disease. J Obstet Gynaecol Can 32: 856-860, 2010.
9. Di Cristofano A and Ellenson LH: Endometrial carcinoma. Annu Rev Pathol 2: 57-85, 2007.
10. Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature 414: 105-111, 2001.
11. Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116: 281-97, 2004
12. Chen X, Liang H, Zhang J, Zen K and Zhang CY: Secreted microRNAs: a new form of intercellular communication. Trends Cell Biol 22: 125-132, 2012.
13. Miska EA: How microRNAs control cell division, differentiation and death. Curr Opin Genet Dev 15: 563-568, 2005
14. Saito Y, Liang G, Egger G, et al: Specific activation of microRNA-127 with downregulation of the proto-oncogene BCL6 by chromatin-modifying drugs in human cancer cells. Cancer Cell 9: 435-443, 2006.
15. Hayashita Y, Osada H, Tatemastu Y, et al: A polycistronic microRNA cluster, miR-17-92, is overexpressed in human lung cancers and enhances cell proliferation. Cancer Res 65: 9628-9632, 2005.
16. Iorio MV, Ferracin M, Liu CG, et al: MicroRNA gene expression deregulation in human breast cancer. Cancer Res 65: 7065-7070, 2005.
17. Chan JA, Krichevsky AM and Kosik KS: MicroRNA-21 is an antiapoptotic factor in human gliobblastoma cells. Cancer Res 65: 6029-6033, 2005.
18. Murakami Y, Yasuda T, Saigo K, et al: Comprehensive analysis of microRNA expression patterns in hepatocellualr carcinoma and non-tumorous tissues. Oncogene 25: 2537-2545, 2006.
19. He H, Jazdzewski K, Li W, et al: The role of microRNA genes in papillary thyroid carcinoma. Proc Natl Acad Sci USA 102: 19075-19080, 2005.
20. Iorio MV, Visone R, Di Leva G, et al: MicroRNA signatures in human ovarian cancer. Cancer Res 67: 8699-8707, 2007.
21. Cohn DE, Fabbri M, Valeri N, et al: Comprehensive miRNA profiling of surgically staged endometrial cancer. Am J Obstet Gynecol 202: 656.e1-656.e8, 2010.
22. Ratner ES, Tuck D, Richter C, et al: MicroRNA signatures differentiate uterine cancer tumor subtypes. Gynecol Oncol 118: 251-257, 2010.
23. Snowdon J, Zhang X, Childs T, Tron VA and Feilotter H: The microRNA-200 family is upregulated in endometrial carcinoma. PLoS One 6: e22828, 2011.
24. Chung TK, Cheung TH, Huen NY, et al: Dysregulated microRNAs and their predicted targets associated with endometrioid endometrial adenocarcinoma in Hong Kong women. Int J Cancer 124: 1358-1365, 2009.
25. Boren T, Xiong Y, Hakam A, et al: MicroRNAs and their target messenger RNAs associated with endometrial carcinogenesis. Gynecol Oncol 110: 206-215, 2008.
26. Chen X, Hu Z, Wang W, Ba Y, et al: Identification of ten serum microRNAs from a genome-wide serum microRNA expression profile as novel noninvasive biomarkers for nonsmall cell lung cancer diagnosis. Int J Cancer 130: 1620-1628, 2012.
27. Li LM, Hu ZB, Zhou ZX, et al: Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res 70: 9798-9807, 2010.
28. Liu R, Zhang C, Hu Z, et al: A five-microRNA signature identified from genome-wide serum microRNA expression profiling serves as a fingerprint for gastric cancer diagnosis. Eur J Cancer 47: 784-791, 2011.
29. Zhang C, Wang C, Chen X, et al: Expression profile of microRNAs in serum: a fingerprint for esophageal squamous cell carcinoma. Clin Chem 56: 1871-1879, 2010
30. Chung TK, Lau TS, Cheung TH, et al: Dysregulation of microRNA-204 mediates migration and invasion of endometrial cancer by regulating FOXC1. Int J Cancer 130: 1036-1045, 2012.
31. Lu J, Getz G, Miska EA, et al: MicroRNA expression profiles classify human cancers. Nature 435: 834-838, 2005.
32. Calin GA, Dumitru CD, Shimizu M, et al: Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 99: 15524-15529, 2002.
33. Chen X, Ba Y, Ma L, et al: Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18: 997-1006, 2008.
34. Mitchell PS, Parkin RK, Kroh EM, et al: Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci USA 105: 10513-10518, 2008.
35. Chim SS, Shing TK, Hung EC, et al: Detection and characterization of placental microRNAs in maternal plasma. Clin Chem 54: 482-490, 2008.
36. Kosaka N, Iguchi H and Ochiya T: Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 101: 2087-2092, 2010.
37. Resnick KE, Alder H, Hagan JP, Richardson DL, Croce CM and Cohn DE: The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol 112: 55-59, 2009.
38. Sun T, Wang Q, Balk S, Brown M, Lee GS and Kantoff P: The role of microRNA-221 and microRNA-222 in androgen-independent prostate cancer cell lines. Cancer Res 69: 3356-3363, 2009.
39. Zhang CZ, Zhang JX, Zhang AL, et al: MiR-221 and miR-222 target PUMA to induce cell survival in glioblastoma. Mol Cancer 9: 229, 2010.
40. Miller TE, Ghoshal K, Ramaswamy B, et al: MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem 283: 29897-29903, 2008.
41. Nikiforova MN, Tseng GC, Steward D, Diorio D and Nikiforov YE: MicroRNA expression profiling of thyroid tumors: biological significance and diagnostic utility. J Clin Endocrinol Metab 93: 1600-1608, 2008.
42. Medina R, Zaidi SK, Liu CG, et al: MicroRNAs 221 and 222 bypass quiescence and compromise cell survival. Cancer Res 68: 2773-2780, 2008.
43. Volinia S, Calin GA, Liu CG, et al: A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci USA 103: 2257-2261, 2006.
44. Bloomston M, Frankel WL, Petrocca F, et al: MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA 297: 1901-1908, 2007.
45. Wu L, Li H, Jia CY, Cheng W, et al: MicroRNA-223 regulates FOXO1 expression and cell proliferation. FEBS Lett 586: 1038-1043, 2012.
46. Myatt SS, Wang J, Monteiro LJ, et al: Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res 70: 367-377, 2010.
47. Goto T, Takano M, Albergaria A, Briese J, et al: Mechanism and functional consequences of loss of FOXO1 expression in endometrioid endometrial cancer cells. Oncogene 27: 9-19, 2008.
48. Giatromanolaki A, Koukourakis MI, Sivridis E, Gatter KC, Harris AL and Banham AH: Loss of expression and nuclear/cytoplasmic localization of the FOXP1 forkhead transcription factor are common events in early endometrial cancer: relationship with estrogen receptors and HIF-1alpha expression. Mod Pathol 19: 9-16, 2006.
49. Myatt SS and Lam EW: The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer 7: 847-859, 2007.